Sai Parenterals IPO: Acquisition Fuels Growth, But Strains Cash & Valuation

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorAnanya Iyer|Published at:
Sai Parenterals IPO: Acquisition Fuels Growth, But Strains Cash & Valuation
Overview

Sai Parenterals Ltd. launched its IPO today, aiming to raise ₹408.79 crore with a price band of ₹372-392. The offering is heavily reliant on the acquisition of Noumed Pharmaceuticals for projected revenue growth from ₹163 crore in FY25 to an estimated ₹850 crore by FY28. However, the company grapples with substantial working capital pressures, evidenced by 282 days of receivables and 111 days of inventory in H1 FY26. At the upper price band, the IPO valuation is steep, trading at approximately 120 times FY25 earnings, moderating to 30 times FY28, contingent on successful integration and execution. Brokerage sentiment is divided, with a flat grey market premium signaling muted listing expectations.

Acquisition Fuels Ambitious Revenue Growth

Sai Parenterals' ambitious revenue forecasts—projecting a jump from ₹163 crore in FY25 to ₹850 crore by FY28—are heavily reliant on its acquisition of Noumed Pharmaceuticals. This strategy aims to tap into the growing global CDMO market, expected to reach $23.3 billion in India by 2026. However, growth through acquisition introduces significant execution risks. The company's modest organic growth before this deal, combined with its dependence on Noumed for future earnings, poses a material risk if integration challenges arise or expected benefits are not realized. The CDMO sector is also shifting focus in 2026 towards specialized, technology-driven capabilities over sheer production volume, a trend Sai Parenterals must manage.

Working Capital Strain and IPO Funding Use

Persistent working capital challenges are a significant concern. With receivables averaging 282 days, largely due to government tender dealings, and inventory at 111 days in H1 FY26, Sai Parenterals faces a prolonged cycle to convert sales into cash. The company plans to use ₹33 crore from IPO funds for working capital and ₹14.3 crore for debt repayment. However, these amounts may be insufficient if sales cycles don't shorten or supplier credit terms tighten. This financial pressure stands in contrast to its ambitious revenue targets, highlighting a tension between growth aspirations and immediate cash needs.

IPO Valuation Faces Scrutiny Against Peers

At the IPO's upper price band of ₹392, Sai Parenterals' valuation is approximately 120 times its estimated FY25 earnings. This figure drops to about 30 times FY28 earnings, but this assumes substantial profit growth, mainly from the Noumed acquisition. Competitors like Innova Captab trade at a Price-to-Earnings (P/E) ratio of around 32.45x, and Gland Pharma at 44.71x, both companies being significantly larger. Sai Parenterals' own P/E is noted at 72.19x, which appears high compared to these peers, particularly given its lower Return on Capital Employed (ROCE) of 9.28%. The Indian pharma and healthcare sector is active with deals. However, the CDMO segment is evolving, moving towards specialized treatments and stricter regulatory compliance. While sector growth is expected, companies must offer more than just competitive pricing to succeed.

Analyst Views Split on Sai Parenterals IPO

Sai Parenterals' future success depends on integrating Noumed effectively, boosting both organic and acquisition-driven growth while managing its working capital challenges. The forecast for lower valuation multiples by FY28 relies on achieving significant profit growth, which still carries execution risks. Brokerage opinions are mixed. Analysts at SBI Securities and Ashika Institutional Equities recommend subscribing for the long term, citing growth potential from the Noumed deal but acknowledging the premium valuation. Swastika Investmart, however, advises 'Avoid,' pointing to a poor risk-reward balance and high valuation. Anand Rathi rates the IPO 'Subscribe-Long Term,' viewing the valuation as fair given the company's history and finances, while noting competition. The flat grey market premium indicates cautious retail investor sentiment ahead of its April 2nd debut.

Disclaimer:This content is for informational purposes only and does not constitute financial or investment advice. Readers should consult a SEBI-registered advisor before making decisions. Investments are subject to market risks, and past performance does not guarantee future results. The publisher and authors are not liable for any losses. Accuracy and completeness are not guaranteed, and views expressed may not reflect the publication’s editorial stance.